Summary of patient data
| Patient no.* | Age | Sex | Duration of disease (years) | FK506 dose(mg/day) | Total MG score | ADL score | Prednisolone daily dose (mg) | Antibody titre (nM) | Previous therapy | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entry | Exit | Entry | Exit | Entry | Exit | Entry | Exit | ||||||
| Patient nos. 1, 3, 4, 6, 8, 11, 12: 104 weeks treatment; no. 13: 96 weeks treatment; nos. 14, 15, 16, 17: 88 weeks treatment | |||||||||||||
| *Patient numbers carried over from previous study.4 | |||||||||||||
| †Alternate day therapy. | |||||||||||||
| AZP, azathioprine; CyA, ciclosporin; CPA, cyclophosphamide; PE, plasmapheresis; IVIg, high dose intravenous γ-globulin | |||||||||||||
| 1 | 41 | F | 15 | 2–3 | 14 | 3 | 3 | 1 | 50/20† | 25/5† | 44 | 22 | |
| 3 | 59 | F | 5 | 3–4.5 | 9 | 12 | 3 | 3 | 5 | 5 | 3.9 | 1.8 | AZP, CyA, CPA, PE |
| 4 | 56 | M | 9 | 3–4 | 5 | 1 | 3 | 1 | 17.5/0† | 10/0† | 38 | 12 | |
| 6 | 50 | M | 7 | 3 | 0 | 1 | 2 | 2 | 15/0† | 7.5/0† | 7.8 | 2.7 | AZP, PE |
| 8 | 49 | F | 31 | 3 | 13 | 11 | 3 | 3 | 20/0† | 20/0† | 69 | 65 | CyA |
| 11 | 46 | F | 8 | 3 | 1 | 0 | 2 | 2 | 25/0† | 12.5/0† | 23 | 19 | |
| 12 | 28 | F | 4 | 3 | 6 | 2 | 2 | 2 | 25/0† | 25/0† | 11 | 12 | |
| 13 | 51 | F | 12 | 3 | 13 | 11 | 2 | 1 | 10 | 10 | 3.2 | 2.1 | AZP |
| 14 | 52 | F | 29 | 3 | 5 | 6 | 2 | 1 | 15/5† | 15/0† | <0.2 | <0.2 | AZP, CPA, PE, IVIg |
| 15 | 50 | F | 18 | 3 | 2 | 1 | 2 | 1 | 40/0† | 35/0† | 0.8 | 0.3 | AZP |
| 16 | 38 | F | 4 | 3 | 16 | 4 | 2 | 2 | 20 | 20 | 11 | 4.2 | AZP, PE |
| 17 | 47 | M | 4 | 3 | 6 | 0 | 2 | 0 | 30/0† | 27.5/0† | 41 | 21 | PE |